| 24th week of 2010 patent applcation highlights part 44 |
| Patent application number | Title | Published |
|---|
| 20100150980 | ANTIMICROBIAL MATERIAL - The present invention relates to nanoparticles containing a non-persistent support material and metallic silver particles on the surface of said support material as further specified in the description; to composites containing said nanoparticles; to the manufacture of said nanoparticles and composites and to the use of said nanoparticles and composites. | 2010-06-17 |
| 20100150981 | SUSTAINED RELEASE SYSTEMS OF ASCORBIC ACID PHOSPHATE - A novel method of preparing a controlled release composition is disclosed. Specifically, the present invention relates to a method of preparing controlled release compositions of ascorbic acid phosphate and absorbable polymers. Also disclosed is a novel controlled release composition of ascorbic acid phosphate made by the method of the present invention. | 2010-06-17 |
| 20100150982 | DEPOSITION OF NANOCRYSTALLINE CALCITE ON SURFACES BY A TISSUE AND CELLULAR BIOMINERALIZATION - Disclosed are articles comprising layered nanocrystalline calcite and methods for forming nanocrystalline calcite layers and compositions comprising nanocrystalline calcite layers. | 2010-06-17 |
| 20100150983 | OUTER LAYER HAVING ENTANGLEMENT OF HYDROPHOBIC POLYMER HOST AND HYDROPHILIC POLYMER GUEST - An outer layer having an entanglement comprising an intermingling of cloaked hydrophilic guest and a hydrophobic polymer host, wherein molecules of the guest have been crosslinked with each other. Under certain circumstances, using complexes of the guest may be desirable or even necessary. The intermingling of the guest and host includes a physical tangling, whether it also comprises crosslinking by primary bonding (e.g., chemical/covalent bonding) there-between. Also a method of producing an outer layer having such an entanglement, including the steps of: temporarily cloaking at least a portion of the hydrophilic groups of the guest; intermingling at least a portion of the cloaked groups with a porous polymeric structure by diffusing the guest with cloaked groups into at least a portion of the structure's pores; within the pores, crosslinking at least a portion of the molecules of the guest with the guest; and removing the cloaking. Cloaking may be performed by silylation or acylation. Intermingling may be performed by producing a mixture of guest and host (whether in solution, powdered, granular, etc., form); next, a crosslinking of the guest with itself is performed; then, the mixture is molded into the outer layer. | 2010-06-17 |
| 20100150984 | BIO-ARTIFICIAL PANCREAS AND A PROCEDURE FOR PREPARATION OF SAME - The present invention generally relates to implantable devices for producing insulin in diabetic animals and to methods of making same. Some embodiments include amphiphilic biomembranes for use in biological applications (e.g., as an alternative and/or supplemental insulin source). Some embodiments also include live insulin-producing cells contained within one or more amphiphilic membranes so as to prevent or diminish an immuno-response and/or rejection by the host. | 2010-06-17 |
| 20100150985 | Dental Implant, Endodontic Instrument, and Dental Filling Material Coated with a Peptide-Based Antimicrobial and Methods of Using and Making the Same - Dental implants and endodontic instruments are coated with an antimicrobial peptide-based coating. Methods of coating the dental implants and endodontic instruments with the antimicrobial peptide-based coating are disclosed together with treating a subject with the coated dental implant and endodontic instruments to prevent or lessen bacterial infections in the subject. | 2010-06-17 |
| 20100150986 | FILM PREPARATION WITH RAPIDLY DISSOLVING PROPERTY AND FLEXIBILITY - The present invention relates to a film preparation having both rapid solubility and flexibility at the same time. The film preparation is characterized by comprising: an active-ingredient-containing layer comprising an active ingredient, a water-soluble polymer selected from the group consisting of methyl cellulose, hydroxypropyl cellulose, and hydroxypropyl methyl cellulose, and a disintegrating agent; and an active-ingredient-free layer comprising methyl cellulose and/or hydroxypropyl methyl cellulose. It is further characterized in that the amount of the active ingredient is 0.1-75.0 mass % of a total mass of the film preparation and a total content of the active ingredient and the water-soluble polymer in the active-ingredient-containing layer is 15.0-95.0 mass % of a total mass of the active-ingredient-containing layer. | 2010-06-17 |
| 20100150987 | Method for Manufacturing Edible Film - The present invention provides a process for making an edible film having a substantially uniform distribution of components, which includes the steps of combining a water-based film polymer solution and a slurry-type mixture comprising a water-active component and a solvent; mixing the polymer solution and slurry-type mixture for about 10 minutes or less; dispensing the mixed solution and slurry-type mixture to form a film; and drying the film to evaporate the water and solvent. Films made by the process are also provided. | 2010-06-17 |
| 20100150988 | FILM-LIKE ORALLY ADMINISTERED MEDICATION AND MANUFACTURING METHOD THEREFOR - Film-like orally administered medications are provided which are less likely to be attached to the oral mucous membrane upon intake and can be easily detached therefrom even if attached thereto. A film-like orally administered medication ( | 2010-06-17 |
| 20100150989 | SUBSTRATES PROVIDING MULTIPLE RELEASES OF ACTIVE AGENTS - The present disclosure comprises a polymeric substrate that provides multiple releases of active agents. A substrate for multiple phase delivery of active agents is provided having a first polymer matrix layer having a first active agent disposed therein, a second polymer matrix layer having a second active agent disposed therein, and a coacervate layer disposed between the first polymer matrix layer and the second polymer matrix layer. Selected first and second active agents are included in the first and second polymer matrices such that as the first and second polymer matrices dissolve, the active agents are released. Multiple phase active agent release is achieved by constructing multiple layers of a polymer matrix containing an active agents formed with polymers having different solubility characteristics or with active agents at different concentration levels. | 2010-06-17 |
| 20100150990 | TREATMENT OF INFLAMMATION AND/OR ENDOTOXIC SHOCK - This invention provides the use of one or more peptides derived from the C-terminal end of a Chemerin protein, or analogs or derivatives thereof for treatment of inflammation and/or endotoxic shock and/or treatment of wounds and/or reduction of levels of inflammatory chemokines in a subject, and one or more peptides derived from the C-terminal end of a Chemerin protein, or analogs or derivatives thereof for use in the treatment of inflammation and/or endotoxic shock, and/or wounds, or for the reduction of levels of inflammatory mediators. | 2010-06-17 |
| 20100150991 | Combination Wound Therapy - A device for providing improved wound healing is described. The device includes a vacuum system for applying a sub-atmospheric pressure to the wound, a gas supply system for applying a gaseous wound healing agent to the wound, and a controller connected with the vacuum system and the gas supply system that controls the applications of the sub-atmospheric pressure and the application of the gaseous wound healing agent to the wound. A method of using the device for improved wound healing is also described. | 2010-06-17 |
| 20100150992 | Methods for Treatment of Ophthalmic Disease of an External Ophthalmic Tissue - A transdermal drug delivery system for treatment of ophthalmic diseases comprising a structure that a plaster layer containing a remedy for ophthalmic diseases is provided on a support, wherein the system is applied to a skin surface including a front surface of an eyelid to administer the remedy for ophthalmic diseases in the plaster layer to an ophthalmic topical tissue by percutaneous permeation substantially without being administered through a systemic blood flow. Use of the transdermal drug delivery system for treatment of ophthalmic diseases, comprising applying the transdermal drug delivery system to a skin surface including a front surface of an eyelid to transfer the remedy for ophthalmic diseases in the plaster layer to an ophthalmic topical tissue by percutaneous permeation substantially without being administered through a systemic blood flow, and a method for transferring the remedy for ophthalmic diseases to the ophthalmic topical tissue. | 2010-06-17 |
| 20100150993 | TRANSDERMAL THERAPEUTIC SYSTEM COMPRISING NORELESTROMIN FOR CONTRACEPTION AND HORMONE REPLACEMENT - The present invention relates to a transdermal therapeutic system for applying the active ingredient norelgestromin onto the skin, optionally in combination with estrogens. It further relates to the use of such systems for hormonal contraception, and for hormone replacement therapy. | 2010-06-17 |
| 20100150994 | AMPHIPHILIC ENTITY NANOPARTICLES - The present invention provides nanoparticle compositions comprising AE nanoparticles. The present invention provides AE nanoparticles comprising one or more amphiphilic entities and pharmaceutical compositions comprising AE nanoparticles. The present invention provides methods of manufacturing AE nanoparticles. The present invention provides methods of delivering a biologically active agent to a subject by administering AE nanoparticles containing a biologically active agent to a subject. | 2010-06-17 |
| 20100150995 | PROCESS FOR THE PRODUCTION OF HIGH-PURITY 2,4'-DIMETHYL-3-PIPERIDINO-PROPIOPHENONE (TOLPERISONE), PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THE LATTER, AS WELL AS ACTIVE INGREDIENT FORMULATIONS THAT CONTAIN TOLPERISONE - The invention relates to a method for producing highly pure 2,4′-dimethyl-3-piperidino-propiophenone (tolperisone) (formula I) and the pharmaceutically acceptable salts, hydrochlorides, and hydrates thereof. The method allows the content of the undesired byproduct 2-methyl-1-(4-methylphenyl) propenone (4-MMPPO) to be kept significantly lower than in previously known methods. The invention further relates to active substance formulations which contain tolperisone and are suitable, among other things, for producing combination preparations used for treating patients suffering from Alzheimer's disease. The invention also relates to topical formulations, controlled release (CR) formulations, and transdermal therapeutic systems, such as active substance patches, which contain less than 50 ppm, preferably less than 10 ppm, more preferably less than 7 ppm, and most preferably less than 3 ppm or 0 ppm (i.e. less than the detectable amount) of the undesired byproduct 2-methyl-1-(4-methylphenyl) propenone (4-MMPPO) in relation to 100 percent by weight of active substance. | 2010-06-17 |
| 20100150996 | ATHLETIC PATCH - The present invention relates to patches for the administration of an athletic supplement to subjects engaged in rigorous exercise or heavy outdoor work. The invention also relates to methods of administering nutrients to subjects using the patch of the invention. | 2010-06-17 |
| 20100150997 | TREATMENT OF ARTHRITIS - A method for treating and/or inhibiting arthritis is provided. The method includes administering an effective amount of a composition including a parathyroid hormone and a pharmaceutically acceptable carrier or salt to a subject with arthritis. Additionally, a method for inhibiting and/or rescuing terminal differentiation of cells is also provided. | 2010-06-17 |
| 20100150998 | VACCINES FOR MALARIA - The present invention relates to a novel lipoprotein particle, methods for preparing and purifying the same, its use in medicine, particularly in the prevention of malarial infections, compositions/vaccines containing the particle or antibodies against the protein particle such as monoclonal or polyclonal antibodies and use of the same, particularly in therapy. In particular it relates to an immunogenic protein particle comprising the following monomers:
| 2010-06-17 |
| 20100150999 | THERAPY OF CANCER BASED ON TARGETING ADAPTIVE, INNATE AND/OR REGULATORY COMPONENT OF THE IMMUNE RESPONSE - The invention relates to a kit of parts, suitable for use in a therapy of cancer, wherein said kit comprises: (i) a recombinant protein comprising one or several polypeptides bearing one or several epitopes of one or several tumor-associated antigens, said polypeptides being inserted in the same or different permissive sites of an adenylate cyclase (CyaA) protein or of a fragment thereof, wherein said CyaA fragment retains the property of said adenylate cyclase protein to target Antigen Presenting Cells or a mixture of such recombinant proteins wherein at least one of said epitopes, or tumor associated antigens, or insertion sites of CyaA protein, or fragment of said CyaA protein is different between the various recombinant proteins in the mixture; and said kit of parts further comprises at least one of the following compounds; (ii) an agent, suitable for modulating a regulatory immune response in a patient ad optionally; (iii) an adjuvant component suitable for activating the innate immune response in a patient. | 2010-06-17 |
| 20100151000 | COMPOSITIONS AND METHODS FOR MODULATING IMMUNE RESPONSES - This invention discloses methods and compositions for modulating immune responses, which involve particulate delivery of agents to immune cells, wherein the agents comprise an inhibitor of the NF-κB signaling pathway and an antigen that corresponds to a target antigen. The methods and compositions of the present invention are particularly useful in the treatment or prophylaxis of an undesirable immune response associated with the target antigen, including autoimmune diseases, allergies and transplantation associated diseases. | 2010-06-17 |
| 20100151001 | ETHYNYLATED HETERODINUCLEOSIDE PHOSPHATE ANALOGS, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF - The invention relates to novel ethynylated heterodinucleoside phosphate analogs, the production thereof, substances containing at least one of said compounds, and the use thereof for the treatment of cancer and infectious diseases. | 2010-06-17 |
| 20100151002 | Guggulphospholipid Methods and Compositions - The present invention relates to the methods for preparing synthetic guggulphospholipids, their fatty acid analogues and other bioactive molecules. The present invention relates to E-guggulsterone and Z-guggulsterone or mixture of E- and Z-guggulsterones. The present invention also provides a novel method for the preparation of E-guggulsterol and Z-guggulsterol or mixture of E- and Z-guggulsterols from a mixture of E- and Z-guggulsterones. The present invention further relates to guggulphospholipids and other bioactive molecules incorporated into complexes such as liposomes, complexes, emulsions, vesicles, micelles, and mixed micelles, which can include other active agents, such as hydrophobic or hydrophilic drugs for use, e.g., in treatment of human and animal diseases. | 2010-06-17 |
| 20100151003 | EGFR BINDING PEPTIDES AND USES THEREOF - Short oligopeptides are provided which are capable of binding to the epidermal growth factor receptor on the surface of human tumor cells. Methods for using the peptides as targeting moieties in more complex compositions, such as conjugates of cytoxins, and/or structures, such as liposomal structures, for the purposes of drug delivery are also provided. | 2010-06-17 |
| 20100151004 | MODULATION OF DRUG SENSITIVITY - Methods for the treatment of disorders, including cancer, are described which include administering to a subject a DNA methylation inhibitor and an antineoplastic agent. Compositions containing a DNA methylation inhibitor and an antineoplastic agent, which are useful in treating disorders including cancer, are also described. Additionally, methods useful for developing a prognosis for or diagnosing a subject's development of resistance to treatment with a chemotherapeutic agent are described. | 2010-06-17 |
| 20100151005 | TARGETED CARRIERS FOR INTRACELLULAR DRUG DELIVERY - The invention provides a method for delivering a cargo molecule into a cell using a targeted DNA-based carrier (e.g., DNA dendrimer). Compositions and kits useful in the practice of the methods are also provided. | 2010-06-17 |
| 20100151006 | CANCER THERAPY SENSITIZER - The present invention relates to compositions and methods for sensitizing cancer therapy. The invention provides such compositions comprising a SPARC family polypeptide or polynucleotide, as well as recombinant cells containing a SPARC family polypeptide or polynucleotide. The compositions and methods of the invention are useful in in vitro study of cancer therapy resistance, as well as ex vivo and in vivo therapy of cancer. | 2010-06-17 |
| 20100151007 | COMPOSITIONS AND METHODS FOR SELECTIVE INHIBITION OF VEGF - Disclosed herein are siRNA compositions and methods useful for inhibiting expression of vascular endothelial growth factor (VEGF) isoforms. Such compositions and methods further involve siRNA capable of selectively targeting angiogenic VEGF isoforms while selectively sparing anti-angiogenic isoforms. Diseases which involve angiogenesis stimulated by overexpression of VEGF, such as diabetic retinopathy, age related macular degeneration and many types of cancer, can be treated by administering small interfering RNAs as disclosed. | 2010-06-17 |
| 20100151008 | Preparations and Methods for Textile and or Fiber Surface Finishing, Surface Finished Articles Prepared Thereby, and Uses Therefor - The invention relates to the use of liposomes, particularly liposomes based on soybean oil lecithins, for finishing textiles and fibers, a key aspect of the invention being that, besides a fiber-care effect, skin-friendly substances are transferred by liposome-finished fibers or textiles to the skin from those fibers or textiles. | 2010-06-17 |
| 20100151009 | FORMULATIONS FOR DELIVERING INSULIN - Oral insulin formulations and processes for preparing oral insulin formulations are provided. | 2010-06-17 |
| 20100151010 | MEDICAMENT IN A MULTILAYER FORM - The invention relates to a medicament in a multilayer form, containing a) a core with a pharmaceutical agent, b) an inner coating, 50 to 95 percent by weight of which arc composed of a (co)polymer comprising 95 to 100 percent by weight of radically polymerized vinylic monomers with neutral side groups and 0 to 5 percent by weight of monomers with anionic side groups, c) an outer coaling made of a copolymer comprising 75 to 95 percent by weight of radically polymerized C | 2010-06-17 |
| 20100151011 | SOLID ORALLY ADMINISTERABLE PHARMACEUTICAL DOSAGE FORMS WITH RAPID ACTIVE PRINCIPLE RELEASE - The present invention relates to solid pharmaceutical dosage forms which can be administered orally and comprise 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide in amorphous form and/or thermodynamically metastable crystal modification and have rapid release of active ingredient, and to process for the production thereof, the use thereof as medicament, the use thereof for the prophylaxis, secondary prophylaxis and/or treatment of disorders, and to the use thereof for producing a medicament for the prophylaxis, secondary prophylaxis and/or treatment of disorders. | 2010-06-17 |
| 20100151012 | STABILISED PHARMACEUTICAL COMPOSITION CONTAINING PREGABALINE - Solid pharmaceutical composition containing: (a) pregabaline as active principle and (b) one or several pharmaceutical auxiliary agents, the composition being essentially free from saccharides and comprising no further amino acids, apart from pregabaline. | 2010-06-17 |
| 20100151013 | Gastric acid secretion inhibiting composition - An oral pharmaceutical dosage form comprises pharmacologically effective amounts of an acid-susceptible proton pump inhibitor and an H2 receptor antagonist in combination with at least on pharmacologically acceptable excipient which causes a delayed release and/or an extended release of the proton pump inhibitor. The H2 receptor antagonist is included in the dosage form in such a way that it is rapidly released after administration. This dosage form is suitable for the treatment of conditions associated with an excessive secretion of gastric acid and provides a suitable combination of a rapid onset and a long-lasting duration of the effect. The invention also relates to a method for manufacturing such a dosage form and to a method for the treatment of conditions associated with the secretion of gastric acid. | 2010-06-17 |
| 20100151014 | PHARMACEUTICAL COMPOSITION - Provided herein are pharmaceutical compositions comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one sequestering polymer are all components of a single unit, and wherein the seal coat forms a layer physically separating the antagonist from the agonist from one another. Methods for manufacturing such a pharmaceutical composition are also provided. Methods for treating pain using such compositions are also demonstrated. | 2010-06-17 |
| 20100151015 | Compositions Comprising Melperone and Controlled-Release Dosage Forms - The present invention is directed to pharmaceutical compositions, and methods of making such compositions, comprising microparticles containing a core comprising melperone and a controlled-release coating. The present invention is also directed to pharmaceutical dosage forms comprising melperone, including orally disintegrating tablets, conventional tablets, and capsules, and methods for their preparation. | 2010-06-17 |
| 20100151016 | METHOD FOR PRODUCING PHARMACEUTICAL TABLET - A process for advantageously producing tablets having an improved release property and an excellent stability to change with time is provided. The process is for producing tablets containing a morphinan compound represented by the Formula (I) below or pharmaceutically acceptable acid addition salt thereof and an acidic substance such as fumaric acid, maleic acid or adipic acid, and characterized in that the morphinan compound or a pharmaceutically acceptable acid addition salt thereof is granulated by wet granulation together with (an) excipient(s) prior to adding the acidic substance thereto. | 2010-06-17 |
| 20100151017 | Oral Preparation With Controlled Release - A pharmaceutical pellet is disclosed, comprising a spherical core containing active ingredient with a smooth surface and a coating on the core which controls the release of the active ingredient in a pH-independent manner. With such a pellet the release of the active ingredient can follow a profile with a lag phase of 60 minutes to 840 minutes, a proportion of 5 wt. % or less of the active ingredient being released during the lag phase. The active ingredient can furthermore be released from the pellet with a profile such that after the lag phase the release of the active ingredient amounts to between 3 and 25 wt. % per hour. | 2010-06-17 |
| 20100151018 | SUSTAINED-RELEASE LEVETIRACETAM COMPOSITION AND PREPARATION PROCESS - A subject of the present invention is a novel formulation of levetiracetam making it possible to obtain a solid pharmaceutical composition, particularly intended for oral administration, for the sustained release of levetiracetam. A subject of the invention is also a process for the preparation of such a pharmaceutical composition. | 2010-06-17 |
| 20100151019 | SOLID COMPOSITION FOR CONTROLLED RELEASE OF IONIZABLE ACTIVE AGENTS WITH POOR AQUEOUS SOLUBILITY AT LOW pH AND METHODS OF USE THEREOF - A novel solid composition and methods for making and using the solid composition are provided. The solid composition comprises: (a) at least one active agent with a solubility of less than about 0.3 mg/ml in an aqueous solution with a pH of at most about 6.8 at a temperature of about 37° C.; and (b) a hydrophilic polymer matrix composition comprising: i) a hydrophilic polymer selected from the group consisting of METHOCEL™, POLYOX™ WSR 1105 and combinations thereof; and optionally ii) a hydrophobic polymer selected from the group consisting of Ethocel 20 premium; and (c) an alkalizer selected from the group consisting of calcium carbonate, magnesium oxide heavy and sodium bicarbonate; wherein the composition provides at least about 70% release of the active between about 7 to about 12 hours following oral administration. | 2010-06-17 |
| 20100151020 | DRUG DELIVERY SYSTEM FOR ZERO ORDER, ZERO ORDER BIPHASIC, ASCENDING OR DESCENDING DRUG DELIVERY OF METHYLPHENIDATE - The invention is directed to a drug delivery device for controlled release of a drug, such as methylphenidate hydrochloride. The drug deliver device has a drug core, having a plug embedded therein, and at least a first coating that at least partially surrounds the core. The plug may be hollow or solid, and swells upon absorption of water, bursting through the first coating. The drag delivery device enables zero-order drug release profiles as well as more complicated release profiles to be obtained. | 2010-06-17 |
| 20100151021 | Compositions Comprising Melperone - The present invention is directed to pharmaceutical compositions, and methods of making such compositions, comprising microparticles containing melperone and/or a pharmaceutically acceptable salt, solvate, or ester thereof; a layer of alkaline buffer, and a controlled-release coating. The present invention is also directed to pharmaceutical dosage forms, including orally disintegrating tablets, conventional tablets, and capsules, and methods for their preparation. | 2010-06-17 |
| 20100151022 | Controlled-release compositions - A solid dosage formulation having a core with a pharmacological agent dispersed in a first controlled-release matrix from which release of the agent is relatively slow; and a coat formed over the core and having the agent dispersed in a second controlled-release matrix from which release of the agent is relatively fast. The first matrix can be a cross-linked high amylose starch and the second matrix can be a mixture of polyvinyl acetate and polyvinylpyrrolidone. | 2010-06-17 |
| 20100151023 | Time delayed release mechanism for energizing composition and method of use - The present invention is directed to a time-release energizing supplement of the present invention comprising energizing ingredients coated by an enteric coating. The energizing ingredients comprise guarana seed extract, eleuthero root extract, tyrosine, and high amounts of B-complex vitamins. The B-complex vitamins preferably comprise thiamin, riboflavin, niacin, vitamin B6, and vitamin B12. The enteric coating of the time-release energizing supplement controls the release of the energizing ingredients inside the user's body and energizes the user by enhancing physical and metal performance over an extended period of time. | 2010-06-17 |
| 20100151024 | THERAPEUTIC AGENT FOR ULCERATIVE COLITIS - A method for treating a patient having ulcerative colitis, by administering a drug which containing an effective amount of tetracyclines is provided. The drug may also contain penicillins and/or metronidazoles. | 2010-06-17 |
| 20100151025 | PREVENTION AND TREATMENT FOR OSTEONECROSIS AND OSTEORADIONECROSIS OF THE JAW - The present invention provides compositions and methods useful for treating, preventing or slowing the progression of ONJ and ORNJ. The invention provides for the use of PDGF in a pharmaceutically acceptable buffer in the preparation of a medicament useful for treating, preventing or slowing the progression of ONJ and ORNJ. The invention provides for the use of PDGF in a pharmaceutically acceptable buffer wherein the PDGF is disposed in a biocompatible matrix in the preparation of a medicament useful for treating, preventing or slowing the progression of ONJ and ORNJ. In one embodiment, a method for treating, preventing or slowing the progression of ONJ or ORNJ comprises providing a composition comprising a PDGF solution disposed in a biocompatible matrix and applying the composition to a desired site in the jaw. In another embodiment, a method for treating, preventing or slowing the progression of ONJ or ORNJ comprises providing a composition comprising a PDGF in a pharmaceutically acceptable buffer and applying the composition to a desired site in the jaw. The present invention also provides kits useful for treating, preventing or slowing the progression of ONJ and ORNJ. | 2010-06-17 |
| 20100151026 | NOVEL STRAIN OF LACTOBACILLUS CRISPATUS - The invention provides a naturally occurring strain of | 2010-06-17 |
| 20100151027 | METHOD OF TREATING PAIN UTILIZING CONTROLLED RELEASE OXYMORPHONE PHARMACEUTICAL COMPOSITIONS AND INSTRUCTION ON DOSING FOR RENAL IMPAIRMENT - The invention pertains to a method of using oxymorphone in the treatment of pain by providing a patient with an oxymorphone dosage form and informing the patient or prescribing physician that the bioavailability of oxymorphone is increased in patients with renal impairment. | 2010-06-17 |
| 20100151028 | CRUSH RESISTANT DELAYED-RELEASE DOSAGE FORMS - The invention relates to a dosage form comprising a physiologically effective amount of a physiologically active substance (A), a synthetic, semi-synthetic or natural polymer (C), optionally one or more physiologically acceptable auxiliary substances (B) and optionally a synthetic, semi-synthetic or natural wax (D), wherein the dosage form exhibits a resistance to crushing of at least 400 N and wherein under physiological conditions the release of the physiologically active substance (A) from the dosage form is at least partially delayed. | 2010-06-17 |
| 20100151029 | Anti-infectious hydrogel compositions - The present invention provides a hydrogel composition capable of preventing the intrusion of micro-organisms into body cavities or body openings of mammals comprising of a poly(N-vinyl lactam), a polysaccharide and water. | 2010-06-17 |
| 20100151030 | Use of MgO Doped with a Divalent or Trivalent Metal Cation for Removing Arsenic from Water - Systems and methods for use of magnesium hydroxide, either directly or through one or more precursors, doped with a divalent or trivalent metal cation, for removing arsenic from drinking water, including water distribution systems. In one embodiment, magnesium hydroxide, Mg(OH) | 2010-06-17 |
| 20100151031 | DISCRETE SIZE AND SHAPE SPECIFIC ORGANIC NANOPARTICLES DESIGNED TO ELICIT AN IMMUNE RESPONSE - The presently disclosed invention is broadly directed to therapeutic micro- and/or nanoparticles designed to target an immune cell with an active agent. More particularly, the particles have a predetermined geometry and a broadest dimension of less than about 10 μm. The immune cell-targeted micro and/or nanoparticles may additionally comprise a biocompatible polymer. | 2010-06-17 |
| 20100151032 | Silver and Zinc Containing Body Care Agent - The invention relates to a body care agent containing metal particles which release zinc and silver ions in said body care agent by contacting body liquid or body humidity and whose metallic silver content at least equal or greater than 99 % (m/m). | 2010-06-17 |
| 20100151033 | OCTREOTIDE DEPOT FORMULATION WITH CONSTANTLY HIGH EXPOSURE LEVELS - The present invention relates to sustained release formulations comprising as active ingredient octreotide or a pharmaceutically-acceptable salt thereof and two different linear polylactide-co-glycolide polymers (PLGAs). | 2010-06-17 |
| 20100151034 | GRANULAR PHARMACEUTICAL COMPOSITION OF ATORVASTATIN FOR ORAL ADMINISTRATION - A granular pharmaceutical composition for oral administration, comprising (1) atorvastatin or a pharmaceutically acceptable salt thereof, (2) a surfactant selected from the group consisting of sodium laurylsulfate and polyoxyethylene hydrogenated castor oil, and (3) a water-soluble polymer, is disclosed. | 2010-06-17 |
| 20100151035 | PHARMACEUTICAL COMPOSITIONS OF POORLY SOLUBLE DRUGS - The present invention relates to a stable pharmaceutical composition of a poorly water-soluble drug with a view to increasing its solubility and bioavailability. The present invention relates to a solid dispersion of a poorly water-soluble drug. | 2010-06-17 |
| 20100151036 | Multiphase drug delivery system - A two-phase drug delivery medium comprising a discontinuous phase and a solid continuous phase, the discontinuous phase comprising a plurality of droplets, each of which comprises a fluid and at least one drug dissolved or suspended within the fluid, and the continuous phase surrounding and encapsulating the discontinuous phase. | 2010-06-17 |
| 20100151037 | METHOD FOR THE PREPARATION OF NANOPARTICLES CONTAINING A POORLY WATER-SOLUBLE PHARMACEUTICALLY ACTIVE COMPOUND - The present application relates to a method for preparing nanoparticles containing a poorly water-soluble pharmaceutically acceptable compound and compositions containing such nanoparticulates. | 2010-06-17 |
| 20100151038 | GRANULAR MATERIAL FOR DOSAGE FORMS - A granular material which has a mean particle diameter of 150 to 800 micrometers; and an unsettled bulk density of 0.1 to 0.35 g/cm3 and/or a compactibility which results in a compact with a tensile strength of at least 1.7 MPa when the granular material is subjected to a compaction pressure of 266 MPa; and wherein the main component of the granular material is a cellulose derivative or an alkylene oxide homo- or copolymer or a blend thereof is useful for preparing dosage forms with a controlled release profile. | 2010-06-17 |
| 20100151039 | SKIN MOISTURIZING AGENT FOR ORAL INTAKE AND FUNCTIONAL FOODS AND DRINKS - The present invention provides functional food and beverage that produce a skin moisturizing effect through oral intake, that is excellently safe, and that may be taken regularly. The invention also provides a skin moisturizer for oral intake to be used in the functional food and beverage, as well as use thereof. The present skin moisturizer for oral intake contains as an active component fermented milk whey obtained by fermentation of milk with | 2010-06-17 |
| 20100151040 | PUTAMEN OVI - The present invention pertains to a method for the preparation of putamen ovi, putamen ovi having a defined grain size distribution, and to the use of putamen ovi for the treatment of calcium deficiency and other disease conditions. | 2010-06-17 |
| 20100151041 | Hypersaturated gas in liquid - Dispersing a gas in a liquid to provide a mixture of saturated, supersaturated or hypersaturated solution to provide a suspension of bubbles containing gas therein. | 2010-06-17 |
| 20100151042 | Materials and Methods for Treating Influenza Infections - The subject invention provides materials and methods for treating various health conditions, including the prevention and/or treatment of an influenza viral infection. In a preferred embodiment, a cysteamine compound and viral therapeutic are concurrently administered to a subject to treat an influenza virus infection. More preferably, a cysteamine compound is concurrently administered with a viral therapeutic to a subject to treat influenza A, influenza B, influenza C virus infections, including avian influenza virus subtypes (such as H5N1 avian influenza virus). | 2010-06-17 |
| 20100151043 | PREPARATION FOR STERILIZATION OR DISINFECTION OF TISSUE - The present invention relates to a preparation for sterilizing or disinfecting a tissue which has an excellent tissue sterilizing or disinfecting ability and is suitable for therapeutic or prophylactic treatment of various diseases caused by a microorganism such as a bacterium or a virus and a method for sterilizing or disinfecting a tissue. The present invention relates to a preparation for sterilizing or disinfecting a tissue and an agent for therapeutic or prophylactic treatment of a periodontal disease, characterized by containing a gas in a nanobubble state. Furthermore, the present invention relates to the above-mentioned preparation for sterilizing or disinfecting a tissue, characterized in that the above-mentioned gas in a nanobubble state is ozone. Furthermore, the present invention relates to a liquid preparation for sterilizing or disinfecting a tissue, characterized by comprising ozone-nanobubble water. | 2010-06-17 |
| 20100151044 | USE OF ISOOSMOTIC SEAWATER-BASED IONIC SOLUTIONS FOR MANUFACTURING MEDICAL DEVICES FOR THE PREVENTION OF COMPLICATIONS OF THE COMMON COLD OR OF THE FLU SYNDROME - A method of using a seawater-based isoosmotic ionic solution for manufacturing a medical device for administering said solution by nasal spray or mist to patients in the remission phase of the common cold or flu syndrome, or to patients suffering from the common cold or flu syndrome, to prevent and/or treat complications of the common cold or flu syndrome is described. | 2010-06-17 |
| 20100151045 | COMPOSITION AND METHOD FOR REDUCING SIDE-EFFECTS OF INDOLE-3-CARBINOL AND DERIVATIVES - A method is provided for reducing side effects while treating a mammal using indole-3-carbinol, which method includes the steps of administering an effective amount of indole-3-carbinol along with side effect-reducing amounts of a side-effect reducing component. A composition is also provided, as are various combinations of side effect-reducing agents. | 2010-06-17 |
| 20100151046 | Disinfectant - A disinfectant comprising the following (a), (b), (c) and (d), but no other microbicidal disinfecting agents intended for microbicidal disinfection: | 2010-06-17 |
| 20100151047 | EFFECT PIGMENTS - Disclosed are yellowing-stable, silver-white effect pigments having high whiteness based on synthetic mica flakes and to the use thereof in paints, lacquers, printing inks, plastics, button pastes, ceramic materials, glasses, for coloring seed, as dopant in laser markings of plastics and papers, as additive for laser welding of plastics, as additive for coloring in the foods and pharmaceuticals sectors and in cosmetic formulations, and for the preparation of pigment compositions and dry preparations. | 2010-06-17 |
| 20100151048 | TOPICAL COMPOSITION AND METHOD FOR THE TREATMENT AND PROPHYLAXIS OF DERMAL IRRITATIONS - A composition and method for the prevention and therapeutic treatment of skin conditions and disorders are disclosed. The composition and method of the invention are particularly directed to the treatment and prevention of dermal irritations. These irritations include, for example, psoriasis, eczema, ichthyosis, pruritus, dryness and dermatitis, which may cause skin to crack, chap or chafe. The composition and method are particularly useful in treating and preventing diaper dermatitis. A therapeutic composition according to the invention includes an agent, which is an enzyme constituent, promoting the synthesis of collagen and the reproduction of cells, particularly skin cells. Such therapeutic agents include, for example, zinc oxide. This agent is generally nonprescription and capable of effectively preventing and treating diaper dermatitis through local or topical application. Therapeutic compositions according to the invention also include both natural and synthetic components, which aid in application, use and treatment. | 2010-06-17 |
| 20100151049 | MATERIALS AND METHODS FOR PREPARATION OF ALKALINE EARTH FERRATES FROM ALKALINE EARTH OXIDES, PEROXIDES, AND NITRATES - The subject invention concerns methods for preparing alkaline earth ferrates and the preparation of hemostatic compositions from alkaline earth ferrates. In one embodiment, the alkaline earth ferrate is strontium ferrate. In one embodiment, methods of the invention comprise heat treating mixtures of alkaline earth oxides and/or peroxides with iron oxides, such as hematite or magnetite. The subject invention also concerns hemostatic compositions produced using metallic oxides that are reacted with alkaline earth oxides and/or peroxides and the methods used to produce the hemostatic compositions. | 2010-06-17 |
| 20100151050 | Method for evaluation of compound using RSK1 - A method for evaluation of a compound comprising the steps of introducing an RSK1 gene into a cell to prepare a cell capable of expressing RSK1, contacting a compound to be evaluated with the cell, and detecting the specific binding of the compound to RSK1; and a compound given by the method. The compound can be used as a potentiator of cisplatin. The method enables to find a gene which acts specifically on a cell of cancer induced by the abnormality in p53 or enhanced MAPK pathway and to evaluate a compound by using the gene. | 2010-06-17 |
| 20100151051 | ANTI-TUMOR DRUG, MEDICAMENT, COMPOSITION, AND USE THEREOF - An active polypeptide comprising the amino acid sequence of SEQ ID NO:4, having an anti-tumour activity, and compositions and methods including the active polypeptide. | 2010-06-17 |
| 20100151052 | Compositions to alleviate herpes virus symptoms - Compositions and methods of preparing and using such compositions to treat the symptoms of herpes virus. | 2010-06-17 |
| 20100151053 | SYSTEM AND METHOD FOR THE DELIVERY OF A SANITIZING FOAM - A spray solution generates a foam to sanitize surfaces. The spray dip solution is a mixture of the solution with carbon dioxide and nitrous oxide in a closed vessel. After ejecting the liquid dip solution mixture from a nozzle a foam is generated from the solution as the solution hits a surface. The spray can be applied to a number of different surfaces. In an embodiment of the invention, the spray can be applied to cow teats without risk of cross-contamination of the nozzle or other equipment. The generated foam remains intact on the teat for a prolonged period of time, increases the area of the teat in contact with the foam during the treatment period and disperses skin-conditioning fats present in the dip treatment, thereby increasing the coverage of the skin conditioner on and within the epidermis of the teat and surrounding areas. | 2010-06-17 |
| 20100151054 | EMULSION LOTION - An emulsion lotion composition including
| 2010-06-17 |
| 20100151055 | Aroma Composition to Reduce or Suppress Undesirable Bitter and Astringent Taste Impressions of Sweeteners - The invention concerns an aroma composition to reduce or suppress a bitter or astringent impression in the oral cavity, comprising (i) one or more sweeteners and (ii) one or more specific bitter-masking aroma substances and/or flavourings and optionally (iii) one or more sweetness intensifying aroma substances and/or sweeteners and optionally (iv) one or more inactive substances or carriers. The invention also concerns a preparation, containing such an aroma composition, the use of an aroma composition for reducing or eliminating a bitter and astringent effect of an artificial sweetener and a corresponding method for reducing or eliminating the bitter and astringent effect of a sweetener. | 2010-06-17 |
| 20100151056 | DIETARY SUPPLEMENTS FOR DECREASING THE LATENT FOREIGN DNA LOAD - In one aspect, the invention presents methods for treating chronic diseases. In a preferred embodiment, the methods feature administration to a subject an effective dose of a dietary supplement that prevents or attenuates microcompetition between a foreign polynucleotide and a cellular polynucleotide or attenuates an effect of such microcompetition, especially, when the foreign polynucleotide is latent in the subject. | 2010-06-17 |
| 20100151057 | MEDICINAL HERBAL EXTRACT HAVING ANTI-OBESITY EFFECT - Disclosed is an anti-obesity active extract obtained from a medicinal plant. More specifically, the extract obtained from lysimachiae foenum-graeci herba (which is a medicinal plant traditionally used in the East) can be used as an active ingredient for a raw material, a functional food, cosmetic, a crude drug, etc. for an obesity preventing or therapeutic agent because the extract can suppress the adipocyte differentiation and decrease the body weight and body fat in an obese animal, thereby suppressing fat accumulation (that is, a factor for obesity). | 2010-06-17 |
| 20100151058 | COMPOSITIONS FOR PRODUCING SATIETY - Long term weight loss can be achieved and maintained with a formulation of over-the-counter life-enhancing dietary supplements. One or more supplements stimulate the release of serotonin within the brain and one or more supplements stimulate the release of cholecystokinin into the bloodstream. The combined potentiating effect of these two mechanisms on satiety enables greater weight loss than that previously achieved by the individual mechanisms acting alone. A third weight loss mechanism can be achieved with the addition of phenylethylamine. Even more effective weight loss formulations can be achieved with the addition of a blue-green algae, such as aphanizomenon flos aqua, to provide a longer lasting weight loss mechanism. | 2010-06-17 |
| 20100151059 | USE OF VITEX AGNUS CASTUS EXTRACTS FOR PREPARING A MEDICAMENT - The present invention relates to the use of fruit extract from | 2010-06-17 |
| 20100151060 | BOTANICAL BUTTER STICK LIP BALM - A stick lip balm with efficacious amounts of natural moisturizer and organoleptic/sensory attributes of lip feel associated with moisturizers and emollients is provided. The lip balm of the invention comprises at least 90% botanically derived materials and can be formed into a stick sufficiently robust to substantially retain the stick shape under normal conditions of shipping, storage and usage. A method of making the stick lip balm is also provided. | 2010-06-17 |
| 20100151061 | METHODS OF USING BENFOTIAMINE AND PYRIDOXAMINE COMPOSITIONS - The present invention provides a composition comprising an effective amount of benfotiamine and an effective amount of pyridoxamine in a suitable vehicle for topical application. The present compositions are useful in improving the appearance of aged skin characterized by wrinkles, loss of elasticity, and hyperpigmentation caused by chronoaging and/or photoaging of skin, by inhibiting particularly skin damage resulting from reactive carbonyl species (RCS), glycation of skin proteins, formation of advanced glycation endproducts (AGEs) and formation of advanced lipoxidation endproducts (ALEs). | 2010-06-17 |
| 20100151062 | Determining nutrients for animals through gene expression - Genetic information of DNA polymorphism, the functional genomic profile and the different response of an animal to a biologically active nutrient are used to identify the biologically active nutrient composition of the diet for an animal. The response to a nutrient exposure is dynamic since it depends upon the polymorphism of nutritionally inducible genes (as SNPs) that can lead to a different effect of the same nutrient in animals having different genotypes. The assessment of the biologically active nutrient composition of the diet arises from using reference data relating to normal healthy animals with different genotypes, target data relating to unhealthy animals with different genotypes, and nutritional data relating to a different effect of biologically active nutritional compounds in animals with different genotypes. Analysis is affected by relating gene, protein or metabolite expression. | 2010-06-17 |
| 20100151063 | SERUM URIC ACID LEVEL-DECREASING AGENT AND FOOD AND DRINK WITH LABEL TELLING THAT FOOD AND DRINK DECREASE SERUM URIC ACID LEVEL - Problem: Providing a composition with an action of decreasing uric acid level in human sera from a residue from distillation of distilled spirits from barley as a material having been disposed so far despite no safety problem, by a simple treatment method suitable for practical industrial-scale production without any complex purification step. | 2010-06-17 |
| 20100151064 | THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES - Described are compounds having a thiazolhydrazide scaffold, pharmaceutically acceptable salts of these compounds and pharmaceutical compositions containing at least one of these compounds together with pharmaceutically acceptable carrier, excipient and/or diluents. Said thiazolhydrazide compounds can be used for prophylaxis and/or treatment of neurodegenerative diseases and conditions. | 2010-06-17 |
| 20100151065 | USE OF A COSMETIC COMPOSITION FOR COMBATING THE EFFECTS OF ELECTROMAGNETIC WAVES ON THE SKIN - The invention relates to the cosmetic use of at least one epidermal differentiation activator for combating the effects of electromagnetic waves on the skin. The invention also relates to a cosmetic treatment process comprising the application, to the skin or the integuments, of a cosmetic composition comprising at least one epidermal differentiation activator for combating the effects of electromagnetic waves on the skin. | 2010-06-17 |
| 20100151066 | COMPOSITION FOR SUPPRESSING APPETITE, IMPROVING TONE AND MOOD, WITH A NATURAL ANTIDEPRESSANT ACTIVITY AND WITH AN ANTIASTHENIC EFFECT - Compositions comprising L-tryptophan, 5-hydroxytryptophan and/or D-Limonene are used for preparing a product suitable for sublingual or nasal administration which is helpful in suppressing appetite in such a manner as to promote weight loss in an individual; such compositions furthermore exhibit an antidepressant activity and an antiasthenic effect which makes them helpful in improving tone and mood and the level of attention in an individual. The compositions preferably comprise phenylethylamine in a synergistic combination which substance is contained in an algal plant extract, preferably of Klamath algae. | 2010-06-17 |
| 20100151067 | AUTOMATED CONTROLLED ATMOSPHERIC PRESSURIZED RESIN INFUSION - An apparatus comprising a vacuum source line, a pressurized fluid source line and an inlet circuit communicative with the vacuum source line and operatively connectable to an inlet container. The apparatus further comprises an outlet circuit communicative with the vacuum source line and operatively connectable to an outlet line. The apparatus also comprises an outer cover circuit communicative with the vacuum source line and operatively connectable to the outer cover. Further, the apparatus comprises an inlet restrictor fluid circuit in communicative with the fluid source line and adapted to control flow between the inlet vacuum container and interior. Moreover, the apparatus comprises a controller operatively connected to the inlet vacuum circuit, the outlet vacuum circuit, the outer cover vacuum circuit and the inlet restrictor fluid circuit for controlling operation of the inlet vacuum circuit, the outlet vacuum circuit, the outer cover vacuum circuit and the inlet restrictor fluid circuit, respectively. | 2010-06-17 |
| 20100151068 | APPARATUS FOR REFURBISHING CYLINDRICAL MEMBERS - The present invention provides an apparatus for allowing the resurfacing a cylindrical member in a printer having a fuser member that is externally heated by a heater roller. The apparatus includes providing a cylindrical member having an outer surface of a high temperature fluorothermoplastic. When it is determined that the outer surface is in need of resurfacing, the fuser member is removed from the printer, and the cylindrical member is mounted in the place of the fuser member. The cylindrical member is rotated at a speed of at least 1 rpm while engaging the outer surface of the fuser member with the heating roller normally used to heat the fuser member at a pressure of at least 5 psi at a temperature of at least 10° C. below the fluorothermoplastic melting temperature for a time sufficient to resurface of the outer surface of the cylindrical member. | 2010-06-17 |
| 20100151069 | TRANSFER DEVICE AND LINEAR-TYPE APPARATUS FOR THE MANUFACTURE OF CONTAINERS - A preform transfer device includes at least one clamp including two levers pivoting between an open position and a closed position and elements for the elastic return of the levers to the closed position. The device includes a mechanism for selectively controlling the opening and closing of the clamp, this mechanism including: a lever spreading member driven by a link including at least one free end able to interact with actuating elements to cause the clamp to open against the force of the elastic return elements, and associated locking elements that are able to move between a locked position in which the clamp is held in the open position and a retracted position in which the clamp is free to close, the locking elements being able to interact with second actuating elements designed to cause the locking element to move from the locked position to the retracted position, to trigger the closure of the clamp. | 2010-06-17 |
| 20100151070 | APPARATUS AND METHODS FOR AUTOMATING MOVEMENT OF MOLD DRAWERS - An automated removal and insertion machine for mold drawers operable with a molding machine is described. The machine includes a frame, a plurality of actuators mounted within the frame, a plurality of encoders, a plurality of electromagnetic effectors, and a controller. The actuators are operable in a substantially horizontal direction for removal and insertion of molds with respect to the molding machine, and movable within the frame in a substantially vertical direction. At least one of the encoders is operably attached to each of the actuators for providing data indicative of a position of the respective said actuators. At least one electromagnetic effector is attached to a terminal end of each of the actuators for engagement with a respective mold. The controller is operable to control movement of the actuators in the substantially horizontal direction and further operable for controlling power applied to the electromagnetic effectors. | 2010-06-17 |
| 20100151071 | Device For Expanding A Tubular Elastic Body - A device for expanding a tubular elastic body, the device comprises a rigid tube to be introduced into at least a part of the elastic body and keep the elastic body in an expanded state, and an expansion means adapted to expand the elastic body and arranged to be introduced into a first end of the rigid tube. The expansion means is adapted to be movable inside the rigid tube and when the expansion means is fully introduced in the rigid tube, the expansion means protrudes at a second end of the rigid tube and thereby forms a transition between the rigid tube and the expansion element. One end of the expansion means is provided with a radially resilient expansion element with a width decreasing in the introduction direction of the expansion means into the first end of the rigid tube. | 2010-06-17 |
| 20100151072 | DIE PLATE AND METHOD FOR MANUFACTURE THEREOF - One or more methods for the manufacture of a die plate of an extruder of a pelletizer for thermoplastic material, with die orifice openings are provided. One or more of the methods can include providing a die plate blank having a die plate base material; producing a functional layer with a reinforcing material in at least one region on at least one side of the die plate blank, and applying the reinforcing material to the die plate base material in the region of the functional layer by laser dispersion. | 2010-06-17 |
| 20100151073 | BLOWING PLANT COMPRISING A NOZZLE PROVIDED WITH A LIP SEALING JOINT - The invention relates to a plant ( | 2010-06-17 |
| 20100151074 | Plastification and injection unit with back-flow barrier - A plastification and injection unit in injection-molding machines for processing of polymer materials, for example rubber, has a plastification screw that is disposed so as to rotate in a screw cylinder, which simultaneously represents the injection piston. The screw cylinder is disposed in an injection cylinder, in an axially displaceable manner. The injection cylinder can be connected with the sprue channel of an injection-molding die by way of a nozzle, and the injection piston has a back-flow barrier. The screw is axially displaceable in the screw cylinder by means of a separate drive. The screw tip projects out of the screw cylinder and has a closure body having a sealing surface for contact with the face surface of the screw cylinder. | 2010-06-17 |
| 20100151075 | FEED HOPPER HAVING ROTATABLE SLEEVE - An exemplary feed copper, configured for introducing plastic granules into a heating cylinder of an injection molding machine, includes a feed duct, a guiding duct communicated with the feed duct, and a sleeve. The sleeve movably wraps around the guiding duct, and have a lateral through hole for conforming with the lateral opening, such that the plastic granules can be accessible via the guiding duct when the lateral through hole is aligned with the lateral opening. | 2010-06-17 |
| 20100151076 | High Protein Soybean Meal - A high protein soybean meal is disclosed. The soybean meal is generated from soybeans that are capable of commercial yields, wherein the meal comprises at least 58% protein on a dry weight basis. The soybean meal of the present invention may also be generated from soybeans comprising a mean whole seed total protein plus oil content of greater than about 64%, on a dry weight basis, wherein the soybean has a yield, under standard agronomic conditions, of at least 30 bushels per acre. Also disclosed is an animal feed containing the soybean meal of the present invention. | 2010-06-17 |
| 20100151077 | METHOD FOR MAKING A FOOD OR BIOTECHNOLOGICAL PRODUCT USING REDOX POTENTIAL REGULATION - The invention concerns a method for producing a food or biotechnological product including one or more steps, said one or more steps being implemented in a medium, said one or more steps implemented in a medium being a fermentation step, which consists in: during at least one of the steps of the method in controlling the redox potential of the medium of the step concerned. Said method is characterized in that it consists in carrying out the process as follows: regulating at a predetermined setpoint level the redox potential of the medium of the step whereof the redox potential is controlled by controlled additions of a process gas into the medium concerned; and proceeding to the step following the step concerned in the process when said setpoint value is reached so as to carry out at least one of said steps of the process in reducing condition and at least one of said steps of the process in oxidizing condition. | 2010-06-17 |
| 20100151078 | PASTA WITH A REDUCED AMOUNT OF DIGESTIBLE STARCH - The invention concerns a method for producing pasta in which the amount of starch that can be digested in the gastrointestinal tract is less than 50%, said method involving the following steps: a) introducing a dry, raw material mixture, which contains starch and protein and comprises flour and/or semolina, together with water, steam and at least one active ingredient into a closed, forced-conveyance reactor, in which mixing produces a moistened raw material mixture which is then subjected to alternating stress by kneading and working under the effects of temperature and pressure during a predetermined dwelling time in the reactor, in order to partly convert the starch into a broken-down or swellable state and together with the protein and the active ingredient to form a matrix that penetrates the pasta thus obtained; b) shaping of the pasta thus obtained into defined pasta shapes; and c) drying of the shaped pasta shapes to produce a pasta product. | 2010-06-17 |
| 20100151079 | TRANS FATTY ACID FREE FAT FOR MARGARINE PRODUCED BY ENZYMATIC INTERESTERIFICATION AND METHOD FOR PREPARING THE SAME - The present invention can provide margarine oil with the enzymatic interesterification reaction, in which trans fatty acid, different from the existing partially hydrogenerated oil, is not formed in the process, and it has solid fat value profile and melting point corresponding to that of partially hydrogenerated oil and contains less than 1% of trans fatty acid, less than 27% of palmitic acid, more than 99% of triglyceride, less than 1% of diglyceride and monoglyceride, less than 1% of trans fatty acid and based on total fatty acid content. Accordingly, the margarine oil of the present invention is eco-friend and has lower trans fatty acid compared to the existing partially hydrogenerated oil and is easily to use for substituting in the ratio of 1:1 because of its physical properties corresponding to that of partially hydrogenerated oil for margarine oil and is also nutritionally excellent since it has lower palmitic acid content than natural palm oil which is usually used as a substitute for the existing margarine oil such as partially hydrogenerated oil. | 2010-06-17 |
